Micreos Group
PrivateLast Round
Series D
Oct 25, 2022
Total Funding Raised
$61.65M
Company Overview
Micreos Group is a biotechnology company that develops targeted antibacterial products based on phage and endolysin technology to replace antibiotics in human health, food safety, and animal health applications.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Fashion & Beauty, D2C Brands, Precision Medicine
Business Model
B2C
Customer Profile
Hardware Sales, Services & Consulting, Subscription SaaS
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Micreos Group Comparables
Compare Micreos Group with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Lysando AG | 79% | |
| BioNTech SE | 71% | |
| Intralytix, Inc. | 70% | |
Micreos Group Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Oct 25, 2022 | ||||
| Series D | Sep 30, 2021 | ||||
| VC Round | Mar 29, 2019 | ||||
| VC Round | Feb 18, 2016 |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 25, 2022
$25M round closed.
- Mar 29, 2019
$34M round raised.
Micreos Group Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Micreos Group's valuation, stock price, and market status.